as 07-08-2024 4:00pm EST
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
Founded: | 2011 | Country: | United States |
Employees: | N/A | City: | CHICAGO |
Market Cap: | 3.8M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 68.7K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.52 | EPS Growth: | N/A |
52 Week Low/High: | $0.30 - $1.47 | Next Earning Date: | 08-09-2024 |
Revenue: | $500,000 | Revenue Growth: | -98.10% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
DGP Co., Ltd. | XCUR | 10% Owner | Feb 29 '24 | Sell | $1.32 | 3,400,000 | $4,488,000.00 | 0 | SEC Form 4 |
XCUR Breaking Stock News: Dive into XCUR Ticker-Specific Updates for Smart Investing
Business Wire
21 days ago
Journal-News, Hamilton, Ohio
a month ago
Motley Fool
a month ago
TechCrunch
a month ago
The Telegraph
a month ago
Simply Wall St.
a month ago
Bloomberg
a month ago
Simply Wall St.
a month ago
The information presented on this page, "XCUR Exicure Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.